MedTrace Logo

Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

NCT04999293 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1505

Last updated 2021-08-10

No results posted yet for this study

Summary

The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.

Conditions

  • Platelet Aggregation Inhibitors
  • Dual Anti-Platelet Therapy
  • Aged
  • Percutaneous Coronary Intervention

Interventions

DRUG

Ticagrelor

Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    lead OTHER

Principal Investigators

  • Shaoke Meng, MD · The First Affiliated Hospital of Dalian Medical University

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2021-08-05
Completion
2021-08-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999293 on ClinicalTrials.gov